Cic edizioni internazionali
Functional Neurology

Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey

Original Article, 253 - 258
doi: 10.11138/FNeur/2013.28.4.253
Tag this article
Abstract
Enhanced HTML Full text PDF
The aim of this survey was to provide an overview of important issues relating to therapeutic strategies based on botulinum toxin type A injection for the treatment of patients with neurological disorders.
Two hundred and ten physicians from neurology and neurorehabilitation units in Italian hospitals answered a questionnaire exploring some clinical aspects of the use of botulinum toxin type A in patients with spasticity/dystonia. 66% of the physicians treated patients with dystonia, 80% treated adults with spasticity, and 35% treated children with cerebral palsy.
Palpation with no instrumental guidance was the injection technique most commonly used for treating patients with dystonia, spasticity and cerebral palsy; 57% of the physicians evaluated patients instrumentally before toxin injection, while 45% assessed postinjection improvements by instrumental means; 78% of the physicians prescribed (when appropriate) rehabilitation procedures after toxin injection. Our results seem to show that the routine use of botulinum toxin in clinics is far from standardized.

Vol. XXXII (No. 1) 2017 January/March

  1. Back to the future: 30th anniversary of deep brain stimulation for Parkinson’s disease
    Pozzi N.G., Pacchetti C.
    doi: 10.11138/FNeur/2017.32.1.005
  2. Recent advances in the molecular genetics of frontotemporal lobar degeneration
    Rainero I., Rubino E., Michelerio A., D'Agata F., Gentile S., Pinessi L.
    doi: 10.11138/FNeur/2017.32.1.007
  3. The coefficient of friction in Parkinson’s disease gait
    Kleiner A., Galli M., Franceschini M., De Pandis M.F., Stocchi F., Albertini G., de Barros R.M.L.
    doi: 10.11138/FNeur/2017.32.1.017
  4. Reappraisal of the F/M amplitude ratio in carpal tunnel syndrome
    Ginanneschi F., Mondelli M., Aretini A., Rossi A
    doi: 10.11138/FNeur/2017.32.1.023
  5. Gait analysis and clinical correlations in early Parkinson’s disease
    Pistacchi M., Gioulis M., Sanson F., De Giovannini E., Filippi G., Rossetto F., Zambito Marsala S.
    doi: 10.11138/FNeur/2017.32.1.028
  6. Vitamin D in amyotrophic lateral sclerosis
    Libonati L., Onesti E., Gori M.C., Ceccanti M., Cambieri C., Fabbri A., Frasca V., Inghilleri M.
    doi: 10.11138/FNeur/2017.32.1.035
  7. A retrospective analysis of 254 acute stroke cases admitted to two university hospitals in Beirut: classification and associated factors
    Lahoud N., Abbas M.-H., Salameh P., Saleh N., Abes S., Hosseini H., Gebeily S.
    doi: 10.11138/FNeur/2017.32.1.041
  8. A 15-year epileptogenic period after perinatal brain injury
    Pisani F., Pavlidis E., Facini C., La Morgia C., Fusco C., Cantalupo G.
    doi: 10.11138/FNeur/2017.32.1.049
  9. In the face of pain there are no heroes. An open letter to the members of the European Parliament about ensuring in the whole Europe high quality care, research, equitable employment opportunities, and socio-economic support for Cluster Headache (CH) pati
    Rossi P., Craven A., De La Torra E.R.
Last Viewed articles: la lista degli ultimi x visitati.
  1. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey
    Smania N., Colosimo C., Bentivoglio A.R., Sandrini G., Picelli A.
    doi: 10.11138/FNeur/2013.28.4.253
credits